论文部分内容阅读
5月17日,全国人大常委会副委员长、两院院士、我国医学界泰斗吴阶平在视察江苏扬子江药业集团时指出,医药企业要主动应对中国加入世贸组织的挑战,瞄准世界一流制药水平,加强拥有自主知识产权创新药物的研究开发,大力推进技术创新,促进中药的现代化、国际化,全面提高我国医药行业的整体水平和竞争能力。他同时还希望江苏医疗卫生体制改革应走在全国前列。 吴阶平指出,加入世贸组织后国内制药行业面临着机遇和挑战,中国医药企业要在竞争中处于有利地位,必须抓住机遇迎头赶
On May 17, NPC Standing Committee Vice Chairman, Academician Wu Jieping and his medical expert Wu Jieping visited Jiangsu Yangtze River Pharmaceutical Group and pointed out that the pharmaceutical enterprises should take the initiative to meet the challenge of China’s accession to the WTO and aim at world-class pharmaceutical standards. We will step up research and development of innovative medicines with independent intellectual property rights, vigorously promote technological innovation, promote the modernization and internationalization of traditional Chinese medicines, and improve the overall level and competitiveness of the pharmaceutical industry in our country. At the same time, he also hoped that the medical and health system reform in Jiangsu should be at the forefront of the country. Wu Jieping pointed out that after the accession to the WTO, the domestic pharmaceutical industry is faced with opportunities and challenges. Chinese pharmaceutical enterprises must take a favorable position in the competition and must seize the opportunity to catch up